Progressive metaplastic and dysplastic changes in mouse pancreas induced by cyclooxygenase-2 overexpression

Neoplasia

Volumn 10, Issue 8, 2008, Pages 782-796

  Colby, Jennifer K L ^a   Klein, Russell D ^b   McArthur, Mark J ^b   Conti, Claudio J ^a   Kiguchi, Kaoru ^a   Kawamoto, Toru ^a   Riggs, Penny K ^a,c   Pavone, Amy I ^a   Sawicki, Janet ^d   Fischer, Susan M ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c TEXAS A AND M UNIVERSITY   (United States)

^d LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; PROSTAGLANDIN E2; RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CHRONIC PANCREATITIS; CLINICAL FEATURE; CONTROLLED STUDY; DIET; DYSPLASIA; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENE SEQUENCE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; METAPLASIA; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; RNA EXTRACTION; STROMA CELL;

EID: 48249102773     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.08330     Document Type: Article

References (84)

1. Lowenfels AB, Maisonneuve P, DiMagno EP, Elitsur Y, Gates LK Jr, Perrault J, and Whitcomb DC (1997). Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst 89, 442-446.
2. Farrow B, Sugiyama Y, Chen A, Uffort E, Nealon W, and Mark Evers B (2004). Inflammatory mechanisms contributing to pancreatic cancer development. Ann Surg 239, 763-769; discussion 769-771.
3. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, and Depinho RA (2006). Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 20, 1218-1249.
4. Maisonneuve P, Lowenfels AB, Mullhaupt B, Cavallini G, Lankisch PG, Andersen JR, Dimagno EP, Andren-Sandberg A, Domellof L, Frulloni L, et al. (2005). Cigarette smoking accelerates progression of alcoholic chronic pancreatitis. Gut 54, 510-514.
5. Schuller HM (2002). Mechanisms of smoking-related lung and pancreatic adenocarcinoma development. Nat Rev Cancer 2, 455-463.
6. Nkondjock A, Krewski D, Johnson KC, and Ghadirian P (2005). Dietary patterns and risk of pancreatic cancer. Int J Cancer 114, 817-823.
7. Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, and Samet JM (2005). Fasting serum glucose level and cancer risk in Korean men and women. JAMA 293, 194-202.
8. Stolzenberg-Solomon RZ, Graubard BI, Chari S, Limburg P, Taylor PR, Virtamo J, and Albanes D (2005). Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA 294, 2872-2878.
9. Jura N, Archer H, and Bar-Sagi D (2005). Chronic pancreatitis, pancreatic adenocarcinoma and the black box in-between. Cell Res 15, 72-77.
10. Slack JM (2007). Metaplasia and transdifferentiation: from pure biology to the clinic. Nat Rev Mol Cell Biol 8, 369-378.
11. Means AL, Meszoely IM, Suzuki K, Miyamoto Y, Rustgi AK, Coffey RJ Jr, Wright CV, Stoffers DA, and Leach SD (2005). Pancreatic epithelial plasticity mediated by acinar cell transdifferentiation and generation of nestin-positive intermediates. Development 132, 3767-3776.
12. Archer H, Jura N, Keller J, Jacobson M, and Bar-Sagi D (2006). A mouse model of hereditary pancreatitis generated by transgenic expression of R122H trypsinogen. Gastroenterology 131, 1844-1855.
13. Zhu L, Shi G, Schmidt CM, Hruban RH, and Konieczny SF (2007). Acinar cells contribute to the molecular heterogeneity of pancreatic intraepithelial neoplasia. Am J Pathol 171, 263-273.
14. Guerra C, Schuhmacher AJ, Canamero M, Grippo PJ, Verdaguer L, Perez-Gallego L, Dubus P, Sandgren EP, and Barbacid M (2007). Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 11, 291-302.
15. Hruban RH, Adsay NV, Albores-Saavedra J, Anver MR, Biankin AV, Boivin GP, Furth EE, Furukawa T, Klein A, Klimstra DS, et al. (2006). Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res 66, 95-106.
16. Schmid RM (2002). Acinar-to-ductal metaplasia in pancreatic cancer development. J Clin Invest 109, 1403-1404.
17. Hruban RH, Takaori K, Klimstra DS, Adsay NV, Albores-Saavedra J, Biankin AV, Biankin SA, Compton C, Fukushima N, Furukawa T, et al. (2004). An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol 28, 977-987.
18. Esposito I, Seiler C, Bergmann F, Kleeff J, Friess H, and Schirmacher P (2007). Hypothetical progression model of pancreatic cancer with origin in the centroacinar-acinar compartment. Pancreas 35, 212-217.
19. Bockman DE, Guo J, Buchler P, Muller MW, Bergmann F, and Friess H (2003). Origin and development of the precursor lesions in experimental pancreatic cancer in rats. Lab Invest 83, 853-859.
20. Schmid RM, Kloppel G, Adler G, and Wagner M (1999). Acinar-ductal- carcinoma sequence in transforming growth factor-alpha transgenic mice. Ann NY Acad Sci 880, 219-230.
21. Greten FR, Wagner M, Weber CK, Zechner U, Adler G, and Schmid RM (2001). TGF alpha transgenic mice. A model of pancreatic cancer development. Pancreatology 1, 363-368.
22. FitzGerald GA (2003). COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2, 879-890.
23. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, and DuBois RN (2005). Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 23, 254-266.
24. Yip-Schneider MT, Barnard DS, Billings SD, Cheng L, Heilman DK, Lin A, Marshall SJ, Crowell PL, Marshall MS, and Sweeney CJ (2000). Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis 21, 139-146.
25. Schlosser W, Schlosser S, Ramadani M, Gansauge F, Gansauge S, and Beger HG (2002). Cyclooxygenase-2 is overexpressed in chronic pancreatitis. Pancreas 25, 26-30.
26. Crowell PL, Schmidt CM, Yip-Schneider MT, Savage JJ, Hertzler DA II, and Cummings WO (2006). Cyclooxygenase-2 expression in hamster and human pancreatic neoplasia. Neoplasia 8, 437-445.
27. Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, Haudenschild C, Lane TF, and Hla T (2001). Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 276, 18563-18569.
28. Klein RD, Van Pelt CS, Sabichi AL, Dela Cerda J, Fischer SM, Furstenberger G, and Muller-Decker K (2005). Transitional cell hyperplasia and carcinomas in urinary bladders of transgenic mice with keratin 5 promoter-driven cyclooxygenase-2 overexpression. Cancer Res 65, 1808-1813.
29. Muller-Decker K, Neufang G, Berger I, Neumann M, Marks F, and Furstenberger G (2002). Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis. Proc Natl Acad Sci USA 99, 12483-12488.
30. Muller-Decker K, Berger I, Ackermann K, Ehemann V, Zoubova S, Aulmann S, Pyerin W, and Furstenberger G (2005). Cystic duct dilatations and proliferative epithelial lesions in mouse mammary glands upon keratin 5 promoter-driven overexpression of cyclooxygenase-2. Am J Pathol 166, 575-584.
31. Muller-Decker K, Furstenberger G, Annan N, Kucher D, Pohl-Arnold A, Steinbauer B, Esposito I, Chiblak S, Friess H, Schirmacher P, et al. (2006). Preinvasive duct-derived neoplasms in pancreas of keratin 5-promoter cyclooxygenase-2 transgenic mice. Gastroenterology 130, 2165-2178.
32. Sandgren EP, Luetteke NC, Palmiter RD, Brinster RL, and Lee DC (1990). Overexpression of TGF alpha in transgenic mice: induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast. Cell 61, 1121-1135.
33. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD, Hitt BA, et al. (2003). Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4, 437-450.
34. Schmied B, Liu G, Moyer MP, Hernberg IS, Sanger W, Batra S, and Pour PM (1999). Induction of adenocarcinoma from hamster pancreatic islet cells treated with N-nitrosobis(2-oxopropyl)amine in vitro. Carcinogenesis 20, 317-324.
35. Jimenez RE, Z'Graggen K, Hartwig W, Graeme-Cook F, Warshaw AL, and Fernandez-del Castillo C (1999). Immunohistochemical characterization of pancreatic tumors induced by dimethylbenzanthracene in rats. Am J Pathol 154, 1223-1229.
36. Ramirez A, Bravo A, Jorcano JL, and Vidal M (1994). Sequences 5′ of the bovine keratin 5 gene direct tissue- and cell-type-specific expression of a lacZ gene in the adult and during development. Differentiation 58, 53-64.
37. Thomson JM and Parrott WA (1998). pMECA: a cloning plasmid with 44 unique restriction sites that allows selection of recombinants based on colony size. Biotechniques 24922-924, 926, 928.
38. Hogan BCF and Lacy E (1986). Manipulating the Mouse Embryo. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
39. Gomez G, Lee HM, He Q, Englander EW, Uchida T, and Greeley GH Jr (2001). Acute pancreatitis signals activation of apoptosis-associated and survival genes in mice. Exp Biol Med (Maywood) 226, 692-700.
40. Gomez G, Englander EW, Wang G, and Greeley GH Jr (2004). Increased expression of hypoxia-inducible factor-1alpha, p48, and the Notch signaling cascade during acute pancreatitis in mice. Pancreas 28, 58-64.
41. Fischer SM, Lo HH, Gordon GB, Seibert K, Kelloff G, Lubet RA, and Conti CJ (1999). Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog 25, 231-240.
42. Jaffee EM, Schutte M, Gossett J, Morsberger LA, Adler AJ, Thomas M, Greten TF, Hruban RH, Yeo CJ, and Griffin CA (1998). Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J Sci Am 4, 194-203.
43. Bockman DE (1997). Morphology of the exocrine pancreas related to pancreatitis. Microsc Res Tech 37, 509-519.
44. Schussler MH, Skoudy A, Ramaekers F, and Real FX (1992). Intermediate filaments as differentiation markers of normal pancreas and pancreas cancer. Am J Pathol 140, 559-568.
45. Emberley ED, Murphy LC, and Watson PH (2004). S100 proteins and their influence on pro-survival pathways in cancer. Biochem Cell Biol 82, 508-515.
46. Moniaux N, Andrianifahanana M, Brand RE, and Batra SK (2004). Multiple roles of mucins in pancreatic cancer, a lethal and challenging malignancy. Br J Cancer 91, 1633-1638.
47. Crawford HC, Scoggins CR, Washington MK, Matrisian LM, and Leach SD (2002). Matrix metalloproteinase-7 is expressed by pancreatic cancer precursors and regulates acinar-to-ductal metaplasia in exocrine pancreas. J Clin Invest 109, 1437-1444.
48. Vu TH and Werb Z (2000). Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev 14, 2123-2133.
49. Nakamura T, Kuwai T, Kim JS, Fan D, Kim SJ, and Fidler IJ (2007). Stromal metalloproteinase-9 is essential to angiogenesis and progressive growth of orthotopic human pancreatic cancer in parabiont nude mice. Neoplasia 9, 979-986.
50. Omary MB, Lugea A, Lowe AW, and Pandol SJ (2007). The pancreatic stellate cell: a star on the rise in pancreatic diseases. J Clin Invest 117, 50-59.
51. Apte MV, Park S, Phillips PA, Santucci N, Goldstein D, Kumar RK, Ramm GA, Buchler M, Friess H, McCarroll JA, et al. (2004). Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells. Pancreas 29, 179-187.
52. Grippo PJ, Nowlin PS, Demeure MJ, Longnecker DS, and Sandgren EP (2003). Preinvasive pancreatic neoplasia of ductal phenotype induced by acinar cell targeting of mutant Kras in transgenic mice. Cancer Res 63, 2016-2019.
53. Jankowski JA, Harrison RF, Perry I, Balkwill F, and Tselepis C (2000). Barrett's metaplasia. Lancet 356, 2079-2085.
54. Tokoro T, Tezel E, Nagasaka T, Kaneko T, and Nakao A (2003). Differentiation of acinar cells into acinoductular cells in regenerating rat pancreas. Pancreatology 3, 487-496.
55. Sphyris N, Logsdon CD, and Harrison DJ (2005). Improved retention of zymogen granules in cultured murine pancreatic acinar cells and induction of acinar-ductal transdifferentiation in vitro. Pancreas 30, 148-157.
56. Liao JD, Adsay NV, Khannani F, Grignon D, Thakur A, and Sarkar FH (2007). Histological complexities of pancreatic lesions from transgenic mouse models are consistent with biological and morphological heterogeneity of human pancreatic cancer. Histol Histopathol 22, 661-676.
57. Strobel O, Dor Y, Alsina J, Stirman A, Lauwers G, Trainor A, Castillo CF, Warshaw AL, and Thayer SP (2007). In vivo lineage tracing defines the role of acinar-to-ductal transdifferentiation in inflammatory ductal metaplasia. Gastroenterology 133, 1999-2009.
58. Perides G, Tao X, West N, Sharma A, and Steer ML (2005). A mouse model of ethanol dependent pancreatic fibrosis. Gut 54, 1461-1467.
59. Schmid RM and Whitcomb DC (2006). Genetically defined models of chronic pancreatitis. Gastroenterology 131, 2012-2015.
60. Saluja AK, Lerch MM, Phillips PA, and Dudeja V (2007). Why does pancreatic overstimulation cause pancreatitis? Annu Rev Physiol 69, 249-269.
61. Al-Aynati MM, Radulovich N, Riddell RH, and Tsao MS (2004). Epithelialcadherin and beta-catenin expression changes in pancreatic intraepithelial neoplasia. Clin Cancer Res 10, 1235-1240.
62. Zeng G, Germinaro M, Micsenyi A, Monga NK, Bell A, Sood A, Malhotra V, Sood N, Midda V, Monga DK, et al. (2006). Aberrant Wnt/beta-catenin signaling in pancreatic adenocarcinoma. Neoplasia 8, 279-289.
63. Herold K, Moser B, Chen Y, Zeng S, Yan SF, Ramasamy R, Emond J, Clynes R, and Schmidt AM (2007). Receptor for advanced glycation end products (RAGE) in a dash to the rescue: inflammatory signals gone awry in the primal response to stress. J Leukoc Biol 82, 204-212.
64. Lohr M, Kloppel G, Maisonneuve P, Lowenfels AB, and Luttges J (2005). Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis. Neoplasia 7, 17-23.
65. Smakman N, Kranenburg O, Vogten JM, Bloemendaal AL, van Diest P, and Borel Rinkes IH (2005). Cyclooxygenase-2 is a target of KRASD12, which facilitates the outgrowth of murine C26 colorectal liver metastases. Clin Cancer Res 11, 41-48.
66. Jhappan C, Stahle C, Harkins RN, Fausto N, Smith GH, and Merlino GT (1990). TGF alpha overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas. Cell 61, 1137-1146.
67. Lewis BC, Klimstra DS, and Varmus HE (2003). The c-myc and PyMT oncogenes induce different tumor types in a somatic mouse model for pancreatic cancer. Genes Dev 17, 3127-3138.
68. Cano DA, Sekine S, and Hebrok M (2006). Primary cilia deletion in pancreatic epithelial cells results in cyst formation and pancreatitis. Gastroenterology 131, 1856-1869.
69. Shintaku M, Arimoto A, and Sakita N (2005). Serous cystadenocarcinoma of the pancreas. Pathol Int 55, 436-439.
70. Strobel O, Z'Graggen K, Schmitz-Winnenthal FH, Friess H, Kappeler A, Zimmermann A, Uhl W, and Buchler MW (2003). Risk of malignancy in serous cystic neoplasms of the pancreas. Digestion 68, 24-33.
71. Kosmahl M, Pauser U, Anlauf M, and Kloppel G (2005). Pancreatic ductal adenocarcinomas with cystic features: neither rare nor uniform. Mod Pathol 18, 1157-1164.
72. Tada M, Kawabe T, Arizumi M, Togawa O, Matsubara S, Yamamoto N, Nakai Y, Sasahira N, Hirano K, Tsujino T, et al. (2006). Pancreatic cancer in patients with pancreatic cystic lesions: a prospective study in 197 patients. Clin Gastroenterol Hepatol 4, 1265-1270.
73. Gomez D, Rahman SH, Won LF, Verbeke CS, McMahon MJ, and Menon KV (2006). Characterization of malignant pancreatic cystic lesions in the background of chronic pancreatitis. JOP 7, 465-472.
74. Volkan Adsay N (2007). Cystic lesions of the pancreas. Mod Pathol 20 (Suppl 1), S71-S93.
75. Kloppel G (2007). Chronic pancreatitis, pseudotumors and other tumor-like lesions. Mod Pathol 20 (Suppl 1), S113-S131.
76. Raut CP, Nawrocki S, Lashinger LM, Davis DW, Khanbolooki S, Xiong H, Ellis LM, and McConkey DJ (2004). Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts. Cancer Biol Ther 3, 1217-1224.
77. Wei D, Wang L, He Y, Xiong HQ, Abbruzzese JL, and Xie K (2004). Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res 64, 2030-2038.
78. Ali S, El-Rayes BF, Sarkar FH, and Philip PA (2005). Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy. Mol Cancer Ther 4, 1943-1951.
79. Jimeno A, Amador ML, Kulesza P, Wang X, Rubio-Viqueira B, Zhang X, Chan A, Wheelhouse J, Kuramochi H, Tanaka K, et al. (2006). Assessment of celecoxib pharmacodynamics in pancreatic cancer. Mol Cancer Ther 5, 3240-3247.
80. El-Rayes BF, Zalupski MM, Shields AF, Ferris AM, Vaishampayan U, Heilbrun LK, Venkatramanamoorthy R, Adsay V, and Philip PA (2005). A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer. Invest New Drugs 23, 583-590.
81. Xiong HQ, Plunkett W, Wolff R, Du M, Lenzi R, and Abbruzzese JL (2005). A pharmacological study of celecoxib and gemcitabine in patients with advanced pancreatic cancer. Cancer Chemother Pharmacol 55, 559-564.
82. Cascinu S, Scartozzi M, Carbonari G, Pierantoni C, Verdecchia L, Mariani C, Squadroni M, Antognoli S, Silva RR, Giampieri R, et al. (2007). COX-2 and NF-κB overexpression is common in pancreatic cancer but does not predict for COX-2 inhibitors activity in combination with gemcitabine and oxaliplatin. Am J Clin Oncol 30, 526-530.
83. Schuller HM, Kabalka G, Smith G, Mereddy A, Akula M, and Cekanova M (2006). Detection of overexpressed COX-2 in precancerous lesions of hamster pancreas and lungs by molecular imaging: implications for early diagnosis and prevention. ChemMedChem 1, 603-610.
84. Funahashi H, Satake M, Dawson D, Huynh NA, Reber HA, Hines OJ, and Eibl G (2007). Delayed progression of pancreatic intraepithelial neoplasia in a conditional Kras(G12D) mouse model by a selective cyclooxygenase-2 inhibitor. Cancer Res 67, 7068-7071.